A Single-Arm Study of the Effect of a 5-day Regimen of Tbo-Filgrastim 10 μg/kg of Body Weight Administered Subcutaneously on Peripheral Stem Cell Mobilization in Healthy Donors
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics
- Acronyms GRANIX
- Sponsors Teva Pharmaceutical Industries
- 08 Nov 2017 Status changed from recruiting to discontinued.
- 01 Sep 2017 Planned End Date changed from 6 Nov 2018 to 11 Apr 2018.
- 01 Sep 2017 Planned primary completion date changed from 29 Jan 2018 to 11 Apr 2018.